DrugPatentWatch Database Preview
Lannett Company Profile
What is the competitive landscape for LANNETT, and what generic alternatives to LANNETT drugs are available?
LANNETT has one hundred and ninety-six approved drugs.
There is one US patent protecting LANNETT drugs.
There are fifteen patent family members on LANNETT drugs in twelve countries and one hundred and forty-five supplementary protection certificates in twelve countries.
Summary for Lannett
| International Patents: | 15 |
| US Patents: | 1 |
| Tradenames: | 143 |
| Ingredients: | 133 |
| NDAs: | 196 |
| Patent Litigation for Lannett: | See patent lawsuits for Lannett |
| PTAB Cases with Lannett as petitioner: | See PTAB cases with Lannett as petitioner |
Drugs and US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett | VITAMIN D | ergocalciferol | CAPSULE;ORAL | 080825-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Lannett Co Inc | CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF | cetirizine hydrochloride | SYRUP;ORAL | 091130-002 | Apr 22, 2011 | OTC | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Lannett Co Inc | RABEPRAZOLE SODIUM | rabeprazole sodium | TABLET, DELAYED RELEASE;ORAL | 090678-001 | Nov 8, 2013 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | URSODIOL | ursodiol | CAPSULE;ORAL | 079082-001 | Dec 15, 2008 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | ALBUTEROL SULFATE | albuterol sulfate | SYRUP;ORAL | 078105-001 | Dec 27, 2006 | AA | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett Co Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 091624-003 | Apr 5, 2013 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Lannett | NEOMYCIN SULFATE | neomycin sulfate | TABLET;ORAL | 060607-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
| ➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
International Patents for Lannett Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2103307 | ➤ Sign Up |
| European Patent Office | 1328251 | ➤ Sign Up |
| Japan | 2004512296 | ➤ Sign Up |
| Canada | 2426883 | ➤ Sign Up |
| Cyprus | 1118946 | ➤ Sign Up |
| Poland | 361673 | ➤ Sign Up |
| Poland | 203828 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Lannett Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0032 | Belgium | ➤ Sign Up | PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506 |
| C/GB12/028 | United Kingdom | ➤ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| C/GB08/020 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023. |
| 80045 | Netherlands | ➤ Sign Up | PRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204 |
| 02C/039 | Belgium | ➤ Sign Up | PRODUCT NAME: ESCITALOPRAM. OXALAT. (INN) ESCITALOPRAM; NATL. REGISTRATION NO/DATE: 7004 IE10 F 3 20020729; FIRST REGISTRATION: SE 17084 20011207 |
| 323 | Luxembourg | ➤ Sign Up | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| /1999 | Austria | ➤ Sign Up | PRODUCT NAME: MONTELUKAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE MONTELUKASTNATRIUM; NAT. REGISTRATION NO/DATE: 1-22765 UND 1-22766 19981030; FIRST REGISTRATION: FI 12766 UND 12767 19970825 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
